



isomiRTar: a comprehensive portal of pan-cancer 5'-isomiR targeting

Stepan Nersisyan^{1,2,3,4}, Aleksandra Gorbonos⁴, Alexey Makhonin⁴, Anton Zhiyanov^{1,4}, Maxim Shkurnikov⁴ and Alexander Tonevitsky^{1,4,5}

¹Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

²Institute of Molecular Biology, The National Academy of Sciences of the Republic of Armenia, Yerevan, Armenia

³Armenian Bioinformatics Institute (ABI), Yerevan, Armenia

⁴Faculty of Biology and Biotechnology, HSE University, Moscow, Russia

⁵Art Photonics GmbH, Berlin, Germany

ABSTRACT

Inaccurate cleavage of pri- and pre-miRNA hairpins by Drosha and Dicer results in the generation of miRNA isoforms known as isomiRs. isomiRs with 5'-end variations (5'-isomiRs) create a new dimension in miRNA research since they have different seed regions and distinct targetomes. We developed isomiRTar (<https://isomirtar.hse.ru>)—a comprehensive portal that allows one to analyze expression profiles and targeting activity of 5'-isomiRs in cancer. Using the Cancer Genome Atlas sequencing data, we compiled the list of 1022 5'-isomiRs expressed in 9282 tumor samples across 31 cancer types. Sequences of these isomiRs were used to predict target genes with miRDB and TargetScan. The putative interactions were then subjected to the co-expression analysis in each cancer type to identify isomiR-target pairs supported by significant negative correlations. Downstream analysis of the data deposited in isomiRTar revealed both cancer-specific and cancer-conserved 5'-isomiR expression landscapes. Pairs of isomiRs differing in one nucleotide shift from 5'-end had poorly overlapping targetomes with the median Jaccard index of 0.06. The analysis of colorectal cancer 5'-isomiR-mediated regulatory networks revealed promising candidate tumor suppressor isomiRs: hsa-miR-203a-3p|+1, hsa-miR-192-5p|+1 and hsa-miR-148a-3p|0. In summary, we believe that isomiRTar will help researchers find novel mechanisms of isomiR-mediated gene silencing in different types of cancer.

Submitted 28 July 2022

Accepted 19 September 2022

Published 17 October 2022

Corresponding author
Stepan Nersisyan, snersisyan@hse.ru

Academic editor
Vladimir Uversky

Additional Information and
Declarations can be found on
page 13

DOI 10.7717/peerj.14205

© Copyright
2022 Nersisyan et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Bioinformatics, Computational Biology, Genomics, Oncology

Keywords IsomiR, MiRNA, TCGA, Web portal

INTRODUCTION

MiRNAs are short non-coding molecules that post-transcriptionally regulate gene expression (*Hobert, 2008*). A mature miRNA associated with a member of the Argonaute proteins family directly binds to a target mRNA, which results in degradation of the mRNA or translation repression (*Nilsen, 2007*). It is known that most of such interactions require base pairing of a miRNA seed region (six nucleotides located at positions 2-7 from the miRNA 5'-end) with a target mRNA (*Bartel, 2009; Agarwal et al., 2015*). Aberrant miRNA expression and targeting were shown to play an essential role in various pathologies, including different types of cancer (*Garzon, Calin & Croce, 2009; Visone & Croce, 2009*).

Previously analyzed miRNA-seq reads revealed the existence of nucleotide sequence variability at 5'- and 3'-ends of mature miRNAs; these variants of miRNAs were termed isomiRs (*Morin et al., 2008*). The main pathway of isomiR biogenesis is related to the miRNA hairpin cleavage by Drosha and Dicer enzymes: because of imprecise cleavage, mature miRNAs could differ from each other by the presence or absence of several nucleotides at their 5'- or 3'-termini (*Neilsen, Goodall & Bracken, 2012*). We recently showed that almost all miRNAs are heterogeneous at their 3'-ends, while inaccurate Dicer cleavage was observed at 42% of miRNA 5'-ends, and inaccurate Drosha 5'-end cleavage was the rarest case (14% of miRNAs) (*Zhiyanov, Nersisyan & Tonevitsky, 2021*).

Since a seed region of a miRNA is located at positions 2-7, even a single nucleotide length variation at the 5'-end could alter the seed sequence, hence altering the targetome of the miRNA. While this is easy to confirm with bioinformatics sequence-based target prediction tools, only a few studies supported this phenomenon by an experiment. Namely, 5'-isomiR overexpression followed by the luciferase reporter assay analysis validated differential targeting for different 5'-isomiRs of miR-101 (*Llorens et al., 2013*), miR-9 (*Tan et al., 2014*), miR-183 (*Telonis et al., 2015*), miR-34/449 (*Mercey et al., 2017*) and miR-411 (*van der Kwast et al., 2020*). However, the role of isomiRs in cancer remains to be uncovered.

To the best of our knowledge, no publicly available databases summarize the results of computational isomiR target prediction. The situation is additionally complicated because most of the existing bioinformatics tools are not suited for large-scale custom target prediction required for non-canonical isomiRs. Given that, we developed isomiRTar (<https://isomirtar.hse.ru>)—the web portal which allows one to explore 5'-isomiR targeting in 31 cancer types from the Cancer Genome Atlas (TCGA). First, we predicted targets of all 5'-isomiRs by two widely used bioinformatics tools: miRDB (*Chen & Wang, 2020*) and TargetScan (*Agarwal et al., 2015*). Then, the interactions between 5'-isomiRs and putative targets were subjected to co-expression analysis in each cancer type. This resulted in the interactions supported by a significant negative correlation in cancer samples. Aside from the web portal implementation, we also analyzed general properties of 5'-isomiR targeting (such as the impact of one nucleotide variation on a targetome) and explored the colorectal cancer 5'-isomiR-gene regulatory network in depth.

MATERIALS & METHODS

TCGA data collection and processing

RNA-seq and miRNA-seq read count tables for primary solid tumor samples were downloaded from the GDC portal (<https://portal.gdc.cancer.gov>). Thirty-one TCGA projects were selected for the downstream analysis (*Table S1*). First, library size normalization of RNA-seq data was independently conducted for each cancer type using edgeR TMM algorithm implementation (*Robinson, McCarthy & Smyth, 2010*), and the default low-expressed gene removal procedure was applied. After normalizing for transcript length, TMM-normalized fragments per kilobase of transcript per million mapped reads (TMM-FPKM) tables were generated. Finally, TMM-FPKM tables were ommllog_2 -transformed.

Processing of miRNA-seq data was started from the 5'-isomiR annotation from *.mirbase21.isoforms.quantification.txt files. For that, pri-miRNA genomic coordinates and local coordinates of canonical mature miRNA sequences were extracted from miRBase v21 (Kozomara, Birgaoanu & Griffiths-Jones, 2019). The standard 5'-isomiR nomenclature was utilized: a number after the “|” character denotes a shift from the canonical 5'-end in the 5'-3' direction. For example, hsa-miR-192-5p|+1 differs from the canonical hsa-miR-192-5p miRNA by the absence of the first nucleotide on its 5'-end. As in the case of mRNA expression data, the edgeR package was used to filter out low expressed isomiRs and generate ommlog2-transformed TMM-normalized reads per million mapped reads (TMM-RPM) tables. It is well known that the overwhelming majority of miRNA sequencing reads correspond to the dozens of the most highly expressed isomiRs (Shao et al., 2010; Nersisyan et al., 2020a). Given that we marked a minimal set of 5'-isomiRs accounting for 95% of sequencing reads in a TCGA project as *highly expressed* (Table S1). A typical read count distribution is presented in Fig. S1 for the TCGA-COAD project.

Sequence- and correlation-based analysis of 5'-isomiR targeting

IsomiR target prediction was conducted with two commonly used tools: miRDB v6.0 (Chen & Wang, 2020) and TargetScan v7.2 (Agarwal et al., 2015).

The custom prediction mode of the miRDB web portal (<http://mirdb.org>) was programmatically called for each isomiR sequence using the Requests module of Python. The default 80 threshold value was set for miRDB target scores to select reliable interactions. Due to the technical limitations in miRDB, target prediction was performed only for isomiRs with a sequence length between 17 and 29 nucleotides.

Publicly available TargetScan Perl scripts and UTR data were obtained from the official web portal (https://www.targetscan.org/vert_72/). Dr. George Bell kindly provided Perl scripts for calculating cumulative weighted context++ scores (CWCS). TargetScan predictions almost always covered miRDB predictions (see Results). Because of that, and since there is no conventional CWCS cut-off value, we equalized the numbers of miRDB/TargetScan predicted targets for each 5'-isomiR. Specifically, for each 5'-isomiR we sorted the predictions according to the CWCS (lowest to highest) and then selected top n entries of the list, where n is the number of targets of this isomiR predicted by miRDB. Finally, filtered miRDB and TargetScan predictions were merged.

For a pair of 5'-isomiR and predicted target, we calculated Spearman's correlation coefficient r between corresponding expression levels in each cancer type. The following thresholds were used to define the significance of interaction: $r < -0.3$, adjusted p -value < 0.05 . The same standard criteria for considering miRNA-target correlation significant was previously used in many works (Hu et al., 2016; Paquette et al., 2019; Nersisyan et al., 2020b). Multiple testing correction was performed differently depending on the analysis purpose:

1. Analysis of a cancer-specific isomiR-target regulatory network. In this case, the Benjamini–Hochberg procedure was applied to the list of p -values corresponding to all putative isomiR-target interactions (referred to as FDR_{global} in the isomiRTar interface).

2. Analysis of specific 5'-isomiR targets or specific target gene regulators in a fixed cancer type (out of other interactions context). In this case, the Benjamini–Hochberg procedure was applied only to the narrow list of corresponding p -values (referred to as FDR_{local} in the isomiRTar interface).

Functional annotation analysis

Functional annotation analysis of gene sets was performed with DAVID 2021 ([Sherman et al., 2022](#)). The default 0.05 cut-off value for FDR was used to select significantly enriched KEGG pathways.

Network and statistical analyses, web portal implementation

Networks were constructed and analyzed using the NetworkX v2.8 Python module ([Hagberg, Schult & Swart, 2008](#)). Maximal cliques of isomiR-isomiR co-expression networks were found with the `find_cliques` function.

SciPy v1.5 Python module ([Virtanen et al., 2020](#)) was used for the statistical analysis. Pandas v1.3 ([McKinney, 2010](#)), NumPy v1.19 ([Harris et al., 2020](#)), Seaborn v0.11 ([Waskom, 2021](#)), and Matplotlib v3.5 ([Hunter, 2007](#)) Python modules were extensively used for the miscellaneous computations and visualization.

Implementation of the isomiRTar website was based on Flask v2.0 Python framework and PostgreSQL database. All isomiRTar source codes have been made available on GitHub (<https://github.com/s-a-nersisyan/isomiRTar>).

RESULTS

Pan-cancer expression landscape of 5'-isomiRs

We compiled the comprehensive list of 1022 5'-isomiRs expressed in 31 cancer types using TCGA miRNA sequencing data. Out of them, 168 5'-isomiRs were marked as highly expressed in at least one cancer type, which included 31 non-canonical isomiRs. Approximately 38% of highly expressed isomiRs (63 entries) were expressed in 10 or more cancer types, including 11 non-canonical 5'-isomiRs: hsa-miR-10a-5p|+1, hsa-miR-10b-5p|+1, hsa-miR-22-3p|+1, hsa-miR-29a-3p|-1, hsa-miR-30a-3p|+1, hsa-miR-30e-5p|+1, hsa-miR-101-3p|-1, hsa-miR-142-3p|+1, hsa-miR-183-5p|+1, hsa-miR-192-5p|+1, hsa-miR-203a-3p|+1. Finally, 18 miRNAs (including almost all representatives of let-7 and miR-30 families) were expressed at high levels in all 31 TCGA projects ([Fig. 1A](#)). The rest of 5'-isomiRs (105 entries, 62%) were expressed in a cancer-specific manner (less than 10 cancers, [Fig. 1B](#)).

In most cases, the high expression of a non-canonical 5'-isomiR was tied with the high expression of its corresponding canonical form. There were only two exceptions: the canonical forms of hsa-miR-302a-5p|+3 and hsa-miR-519a-5p|-1 (both were highly expressed in TCGA-TGCT) were not detectable in the analyzed data, suggesting “incorrect” miRBase annotation or systematical sequencing biases. Interestingly, several miRNAs had three highly expressed 5'-isomiRs: hsa-miR-10a-5p (|-1, |0, |+1), hsa-miR-199a-3p (|-1, |0, |+1), hsa-miR-199b-3p (|-1, |0, |+1), hsa-miR-375 (|-1, |0, |+1), hsa-miR-514a-3p (|-3, |-2, |0) and hsa-miR-9-5p (|0, |+1, |+2).




Figure 1 Pan-cancer expression distribution of 5'-isomiRs. (A) Binarized expression profiles of 63 abundantly expressed 5'-isomiRs (highly expressed in ten or more cancer types). (B) Binarized expression profiles of 105 cancer-specific 5'-isomiRs (highly expressed in less than 10 cancer types). Blue cells stand for highly expressed 5'-isomiRs.

Full-size [DOI: 10.7717/peerj.14205/fig-1](https://doi.org/10.7717/peerj.14205/fig-1)

Large-scale sequence-based prediction of 5'-isomiR target genes

We applied two state-of-the-art tools (miRDB and TargetScan) to predict target genes for all considered 5'-isomiRs. The tools are based on different ideas: the miRDB machine learning algorithm was trained on RNA-seq data of HeLa cells transfected with 25 miRNA mimics to predict miRNA targets based on binding site sequence and structure (Liu & Wang, 2019). TargetScan algorithm also scores miRNA bindings sites according to their cross-species conservation (Agarwal et al., 2015). TargetScan systematically yielded a significantly higher number of isomiR targets than miRDB, and the majority of miRDB targets were included in TargetScan predictions: median 95.5% with 95% confidence interval (CI) 85.7–100.0%. To harmonize these data, we equalized the numbers of predicted targets for each 5'-isomiR by selecting the respective number of the best-ranked targets according to TargetScan (see Materials and Methods for details). After such a harmonization, the predictions of miRDB and TargetScan had a median of 26.5% common targets, 95% CI [0.0–48.9]% (Fig. 2A). From here onwards, we consider the union of predictions by miRDB and TargetScan for each 5'-isomiR, unless indicated otherwise.




Figure 2 Predicted targets of 5'-isomiRs. (A) Distribution of the percentage of common miRDB/TargetScan targets. (B) Distribution of the number of predicted 5'-isomiR targets. (C) Distribution of the Jaccard indices calculated for the sets of predicted targets for the pairs of adjacent 5'-isomiRs. (D–F) Targetomes of the representative adjacent 5'-isomiRs.

Full-size [DOI: 10.7717/peerj.14205/fig-2](https://doi.org/10.7717/peerj.14205/fig-2)

The number of sequence-based predicted targets significantly varied between 5'-isomiRs. The median number of targets was 209, and 95%-CI was wide: 6-1082 (Fig. 2B). The canonical form of hsa-miR-3613-3p had the highest number of putative target genes (2551), while five isomiRs had no targets which passed the defined predictions significance thresholds: hsa-miR-1307-5p|0, hsa-miR-1307-3p|+2, hsa-miR-1307-3p|0, hsa-miR-1307-3p|+1 and hsa-miR-371a-3p|+2.

We used the sequence-based predictions to assess the impact of one nucleotide difference in a miRNA 5'-end on its targetome. For each pair of 5'-isomiRs that differ in one nucleotide shift from the 5'-end (*adjacent 5'-isomiRs*), we calculated the Jaccard index (JI) for the sets of putative targets—the size of the intersection divided by the size of the union of the predicted target sets (Gösgens *et al.*, 2021). $JI = 1$ indicates the complete equality of the target sets, $JI = 0$ indicates that the target sets are disjoint and intermediate values between 0 and 1 indicate the degree of the overlap. For example, the Jaccard index for two 5'-isomiRs with 20 common and 60 targets each equals $20 / (60 + 60 - 20) = 0.2$. Surprisingly, the median Jaccard index was equal to 0.06, 95% CI [0.00–0.31], indicating the average poor intersection between targetomes of adjacent 5'-isomiRs (Fig. 2C). Thus, different 5'-isomiRs originating from the same hairpin can generally be considered as independent

functional units. Representative pairs of adjacent 5'-isomiRs are shown in Fig. 2: hsa-miR-10b-3p|0, hsa-miR-10b-3p|+1 (no common targets, Fig. 2D), hsa-miR-101-3p|0, hsa-miR-101-3p|+1 (median overlap with JI = 0.06, Fig. 2E) and hsa-miR-590-3p|-1, hsa-miR-590-3p|0 (maximum overlap with JI = 0.39, Fig. 2F). Next, we searched for nucleotide motifs associated with high values of JI. For that, 6-mer seed regions of the adjacent 5'-isomiRs were merged into 7-mer sequences (*merged seed regions*). Then, duplicate merged seed regions originating from closely related mature miRNAs (*e.g.*, hsa-miR-19a-3p and hsa-miR-19b-3p) were removed. It turned out that 49 out of 50 merged seed regions corresponding to 50 adjacent 5'-isomiRs with the highest JI values started with uracil (χ^2 test $p = 1.29 \times 10^{-30}$). Interestingly, we did not find any motifs for the seed sequences of adjacent 5'-isomiRs with non-overlapping targetomes.

Pan-cancer correlation analysis of 5'-isomiRs and their target genes

The conducted sequence-based target prediction allowed us to compare the putative non-cancer-specific targetomes of 5'-isomiRs. To determine which predicted targets could be downregulated by the corresponding 5'-isomiRs on transcriptome level, we selected isomiR-gene interactions with a significant negative correlation of corresponding expression levels in a set of TCGA samples (the analysis was separately performed for each cancer type). As a result, we could construct the 5'-isomiR-gene interaction networks for each cancer from TCGA. For a given 5'-isomiR and cancer type, we denote the number of significantly anti-correlated 5'-isomiR targets (*i.e.*, the out-degree) as *5'-isomiR targeting activity (ITA)*.

ITA values substantially varied between cancer types, but generally, the median ITA did not exceed 10 (Fig. 3A), which was an order of magnitude lower than the median number of sequence-based predicted targets. Nevertheless, there were several isomiRs with broad functional activity (ITA >100) in almost all cancers. The number of sequence-based predicted targets was the primary determinant of ITA: the corresponding Spearman's correlation coefficients were all positive and significantly different from zero for all cancers (see the vertical axis labels in Fig. 3A). Interestingly, these coefficients strongly varied between cancer types from 0.29 (TCGA-CHOL) to 0.79 (TCGA-TGCT) and were significantly correlated with the median ITA values (Spearman's correlation = 0.8, $p = 4.71 \times 10^{-8}$).

Expression levels of 5'-isomiRs also positively and statistically significantly correlated with ITA for all cancer types ($p < 10^{-3}$), though correlation coefficients were not high (between 0.2 and 0.3, Fig. 3B). We hypothesized that some low-expressed 5'-isomiRs had high ITA because of a co-expression with other active molecules. Given this, we first identified 5'-isomiR co-expression modules in each cancer type. Modules were defined as maximal cliques in corresponding co-expression graphs, where two isomiRs were connected with an undirected edge if absolute Spearman's correlation between their expression levels exceeded 0.5. Then, a representative 5'-isomiR with the highest median expression level was selected from each module. Limiting the analysis to these representative isomiRs systematically increased the correlation values between ITA and average expression in all except two cancer types (Fig. 3B). Notably, there was a complete




Figure 3 Pan-cancer 5'-isomiR targeting activity (ITA) analysis. (A) Distribution of ITAs across different cancer types. The vertical axis labels contain Spearman's correlation coefficients between ITAs and numbers of sequence-based predicted targets. (B) Distribution of Spearman's correlation coefficients between ITAs and median 5'-isomiR expression levels.

Full-size DOI: 10.7717/peerj.14205/fig-3

absence of correlation between ITA and expression in the set of highly expressed 5'-isomiRs in each cancer, indicating that high expression is a necessary but insufficient condition for the downregulation of multiple target genes. The same holds for 18 miRNAs with high expression in all 31 cancer types: ITA values varied from less than ten anti-correlated targets (hsa-miR-100-5p, hsa-miR-99b-5p, hsa-miR-10b-5p) to dozens and hundreds (Fig. S2). Indeed, low values of ITA do not imply the absence of isomiR activity, *e.g.*, in the case of very target-specific regulation.

Overview of isomiRTar portal

To make the 5'-isomiR pan-cancer expression profiles and the results of targeting analysis easily accessible, we developed the isomiRTar web portal (<https://isomirtar.hse.ru>). The portal's main page contains the forms for the five query modes: by cancer type, by 5'-isomiR, by gene, by 5'-isomiR, gene, and cancer triple.

The main feature of the “query by cancer” page is an interaction network between 5'-isomiRs and their target genes in a specified cancer type. As the network is highly interactive, a user can retrieve information about a 5'-isomiR, target gene, or their interaction by simply hovering over corresponding nodes or edges (Fig. 4A). Aside from the graphical representation, the page contains summary statistics for 5'-isomiRs in a selected cancer: median expression, number of predicted targets, number of predicted targets supported by the significant negative correlation. The second query type allows one to explore a pan-cancer expression profile for all 5'-isomiRs of a specified miRNA (Fig. 4B).




Figure 4 Overview of the isomiRTar portal. (A) The fragment of the colorectal cancer interaction network. (B) The pan-cancer expression distribution of hsa-miR-192-5p 5'-isomiRs. (C) Target prediction and correlation analysis results for hsa-miR-192-5p+1 in colorectal cancer. (D) The joint expression distribution plot for hsa-miR-192-5p and its target gene MSN in colorectal cancer. (E) The network of "universal" (not cancer-specific) isomiR-gene interactions. Green nodes represent canonical 5'-isomiRs, red nodes represent non-canonical 5'-isomiRs, and blue nodes represent target genes. Edge colors are inherited from adjacent 5'-isomiRs. The size of a node linearly depends on its out-degree. The width of an edge linearly depends on number of cancers with significant negative correlation.

Full-size DOI: [10.7717/peerj.14205/fig-4](https://doi.org/10.7717/peerj.14205/fig-4)

The analysis of targets for a given 5'-isomiR or 5'-isomiR regulators of a given mRNA can be performed in two modes: cancer-specific or pan-cancer. In the first case, the portal page contains a table with the results of correlation analysis between a selected 5'-isomiR and its predicted targets or predicted 5'-isomiR regulators and a selected target gene (Fig. 4C). By clicking to interaction, a user can see the scatterplot of corresponding expression values (Fig. 4D).

In the second case (pan-cancer mode), isomiR-target interactions are sorted according to the number of cancers, where we observed the significant anti-correlation between corresponding expression levels. Thus, "universal" (not cancer-specific) isomiR-gene interactions can be inferred from isomiRTar. To analyze the landscape of such "universal" interactions, we selected abundantly expressed 5'-isomiRs (highly expressed in 10 or more cancer types) and incident interactions, which were supported by significant negative correlations in at least half of the cancers where the corresponding 5'-isomiR was highly expressed. The resulting network is illustrated in Fig. 4E. Aside from crucial and extensively studied interactions such as the downregulation of ZEB1 and ZEB2 by miR-200 (Hill, Browne & Tulchinsky, 2013; Nersisyan et al., 2021b), the network had several regulatory

interactions mediated by non-canonical 5'-isomiRs: hsa-miR-29a-3p|-1, hsa-miR-101-3p|-1 and hsa-miR-192-5p|+1. The regulation of centrosomal protein 55 (CEP55) by hsa-miR-101-3p|-1 was the most pan-cancer conserved: a significant negative correlation was observed in 15 cancer types. Since CEP55 is a well-studied oncogene (*Jeffery et al., 2016*), this 5'-isomiR of hsa-miR-101-3p acted as a potential tumor suppressor, which agrees with the tumor suppressor role of the canonical hsa-miR-101-3p form (*Wang et al., 2018*).

The interaction network of 5'-isomiRs and their targets in colorectal cancer

We selected colorectal cancer (TCGA-COAD) to illustrate the detailed analysis of 5'-isomiR-gene interaction network (*Fig. 5*). Out of 55 highly expressed isomiRs 39 molecules (71%) had at least one anti-correlated target gene. While most nodes corresponded to canonical miRNAs, four non-canonical 5'-isomiRs had high out-degrees: hsa-miR-142-3p|+1 (ITA = 34), hsa-miR-22-3p|+1 (ITA = 31), hsa-miR-203a-3p|+1 (ITA = 17) and hsa-miR-192-5p|+1 (ITA = 12). Consistent with the sequence-based target prediction, targetomes of the adjacent 5'-isomiRs had a little or no overlap: seven common targets of hsa-miR-203a-3p|0 and hsa-miR-203a-3p|+1 (JI = 0.17), two common targets of hsa-miR-143-3p|-1 and hsa-miR-143-3p|0 (JI = 0.29), one common target for hsa-miR-192-5p|0 and hsa-miR-192-5p|+1 (JI = 0.04), while the rest of adjacent 5'-isomiR pairs did not share target genes.

We selected two pairs of adjacent 5'-isomiR to analyze the cancer-related targeting: hsa-miR-203a-3p (|0, |+1) and hsa-miR-192-5p (|0, |+1). Interestingly, all these isomiRs showed clear tumor-suppressive patterns. Both canonical and non-canonical isomiRs targeted well-known drivers of tumor progression, including master regulators of epithelial-mesenchymal transition (EMT), such as ZEB1 and ZEB2 (see 'Discussion' for details).

Next, we used sets of anti-correlated target genes as an input for the functional enrichment analysis. The significant findings were regulatory interactions mediated by hsa-miR-148a-3p|0: multiple pro-cancer pathways were enriched in the set of its target genes. This included focal adhesion (KEGG hsa04510), ECM-receptor interaction (hsa04512), TGF- β signaling pathway (hsa04350), and PI3K-Akt signaling pathway (hsa04151). Furthermore, the mentioned pathways shared many hsa-miR-148a-3p|0 targets: COL4A1, ITGA5, ITGA11 and LAMB2 were present in three pathways, FLT1 and ROCK1 were present in two pathways, while CSF1, FBN1, LTBP1, and TGFB2 were pathway-specific. Thus, we showed that the canonical miRNA hsa-miR-148a-3p potentially suppresses colorectal tumors.

DISCUSSION

We developed isomiRTar—the user-friendly web portal containing information about the pan-cancer 5'-isomiRs activity. With the use of isomiRTar, researchers can promptly retrieve sequence-based target/regulator predictions and analyze co-expression profiles of putative isomiR-gene interactions in 31 types of cancers. Furthermore, the implemented pan-cancer integration of targeting information allows one to reveal “cancer-conserved”




Figure 5 Interaction network of highly expressed 5'-isomiRs and their target genes in colorectal cancer. Green nodes represent canonical 5'-isomiRs, red nodes represent non-canonical 5'-isomiRs, and blue nodes represent target genes. Edge colors are inherited from adjacent 5'-isomiRs. The size of a node linearly depends on its out-degree.

Full-size  DOI: [10.7717/peerj.14205/fig-5](https://doi.org/10.7717/peerj.14205/fig-5)

regulatory interactions supported by negative correlations of the corresponding expression values in multiple cancers.

To the best of our knowledge, two alternative isomiR web portals exist. Tumor IsomiR Encyclopedia (TIE) contains the results of pan-cancer TCGA analysis of 5'- and 3'-isomiR expression data in a web portal with multiple query and visualization modes (Bofill-De Ros *et al.*, 2021). However, TIE lacks the possibility of isomiR target prediction and analysis. Another database, IsomiR Bank (Zhang *et al.*, 2016), summarizes 308919 isomiRs detected from 2,727 samples with miRNA-seq, including expression data and target predictions with the miRanda tool (Betel *et al.*, 2008). Nevertheless, the predictions available in IsomiR Bank are sequence-based and do not account for tissue or cancer specificity. Thus, we believe the developed isomiRTar portal will bring many new possibilities for the isomiR community.

The data generated by TCGA isomiR expression analysis and miRDB/TargetScan target predictions allowed us to infer several features of 5'-isomiR expression and targeting. Out of 1,022 unique 5'-isomiRs detected in the union of analyzed samples, 168 were marked

as highly expressed in at least one cancer. More than half (62%) of these isomiRs had cancer-specific expression patterns, while the rest were abundantly expressed in ten or more cancer types. The high percentage of cancer-specific 5'-isomiRs agrees well with the recent study by Telonis et al. They showed that different TCGA cancers could be accurately discriminated based on the information about the “high” or “low” expression of each isomiR in a sample (Telonis et al., 2017).

Our work's median number of sequence-based 5'-isomiR targets was 209, 95% CI [6–1082] (Fig. 2B). The previous studies reported that a typical miRNA has from 200 to 606 targets on average, depending on the target prediction strategy (Lewis, Burge & Bartel, 2005; Krek et al., 2005; Chen & Wang, 2020), which is comparable with our estimates for 5'-isomiRs. After applying cancer-specific correlation analysis the median number of genes regulated by a 5'-isomiR decreased to dozens, though this quantity termed ITA varied dramatically between cancer types (Fig. 3A). Together with the weak (though positive and statistically significant) correlation between isomiR expression and ITA, these observations justified the use of pan-cancer correlation analysis and showed the insufficiency of non-specific sequence-based target prediction.

The large-scale prediction of 5'-isomiR targets allowed us to assess the impact of 1 nucleotide variation at a 5'-end of an isomiR on its targetome. The median Jaccard index for the targetomes of the adjacent 5'-isomiRs was equal to 0.06, 95% CI [0.00–0.31] (Fig. 2C). Although we did not find a similar large-scale analysis in the literature, the authors of small-scale studies also reported poor overlaps between 5'-isomiRs with one nucleotide difference: JI = 0.16 for miR-411 (van der Kwast et al., 2020), JI = 0.19 for miR-9, JI = 0.28 for miR-302a (Tan et al., 2014). Note that differences between predicted targetome overlaps could be due to target prediction tools and their internal thresholds.

Aside from pan-cancer analyses, we applied isomiRTar to explore the 5'-isomiR-mediated regulatory network in colorectal cancer (TCGA-COAD project). Among eight highly expressed 5'-isomiRs, we paid special attention to miR-203a and miR-192. Both canonical and non-canonical forms of hsa-miR-203a-3p downregulated genes related to EMT: hsa-miR-203a-3p|+1 targeted transcription factor ZEB1, the master-regulator of EMT (Dongre & Weinberg, 2019), while hsa-miR-203a-3p|0 targeted ADAM12, well-known inducer of EMT (Ruff et al., 2015). A similar targeting profile was observed for hsa-miR-192-5p: the canonical form bound EMT master-regulator ZEB2 (Dongre & Weinberg, 2019) and angiogenesis stimulator WNK1 (Sie et al., 2020), while non-canonical 5'-isomiR regulated two other colorectal cancer oncogenes: NOX4 (Lin et al., 2017) and MSN (Kim et al., 2012). Another interesting finding was related to the targeting activity of hsa-miR-148a-3p|0. Specifically, functional annotation of the anti-correlated target genes list revealed strong enrichment of pathways related to adhesion, ECM-receptor interaction, the TGF- β signaling pathway, and the PI3K-Akt signaling pathway. We previously showed that the hypoxic microenvironment induced miR-148a downregulation in colorectal cancer cells (Nersisyan et al., 2021a), and several reports described the possible mechanisms underlying miR-148a-induced gastrointestinal cancer suppression (Li et al., 2016). These findings suggest the clear tumor-suppressive role of miR-148a in colorectal cancer. Indeed, rigorous validation of the proposed isomiR-target interactions is warranted.

Our study has several limitations. First, the used target prediction tools consider miRNA binding sites only in 3'-UTR regions of putative mRNAs. However, strong experimental evidence of miRNAs binding within coding sequences and 5'-UTRs exists (*Forman & Collier, 2010; Fang & Rajewsky, 2011; Clark et al., 2014*). Therefore, incorporating alternative target prediction tools that cover mRNA regions beyond 3'-UTR, e.g., RNA22 (*Miranda et al., 2006*), is an essential direction for future isomiRTar development. Next, we note that some of the analyzed samples are heterogeneous (e.g., breast tumors), and it is not possible yet to analyze different cancer subtypes separately. Inclusion of major subtypes for some cancers is also a priority feature for new versions of isomiRTar. Finally, we covered only 5'-isomiRs in our analysis since 3'-end variability does not affect the seed region of miRNAs. Yu and co-authors showed that miR-222 isomiRs differing by four nucleotides at the 3'-end play a distinct role in breast cancer (*Yu et al., 2017*). Though we acknowledged the existence of such studies, we decided to give preference to the conciseness of isomiRTar and did not consider 3'-end variations.

CONCLUSIONS

In the present work, we introduce a new interactive database, isomiRTar (<https://isomirtar.hse.ru>), allowing researchers to analyze the interplay between 5'-isomiRs and their target genes in human cancer. The database contains the results of comprehensive bioinformatics analysis, including sequence-based 5'-isomiR target prediction and pan-cancer TCGA analysis.

ACKNOWLEDGEMENTS

The authors thank Phillippe Loher from Computational Medicine Center, Thomas Jefferson University for useful comments and discussions. The authors thank Olga Kolodeeva and Oksana Kolodeeva from Faculty of Biology and Biotechnology, HSE University for the help with testing the isomiRTar portal.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The research was performed within the framework of the “Creation of Experimental Laboratories in the Natural Sciences Program” at HSE University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:
HSE University.

Competing Interests

Stepan Nersisyan is an employee of Armenian Bioinformatics Institute (ABI). Alexander Tonevitsky is an employee of Art Photonics GmbH.

Author Contributions

- Stepan Nersisyan conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Aleksandra Gorbonos performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Alexey Makhonin performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Anton Zhiyanov performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Maxim Shkurnikov conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Alexander Tonevitsky conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

Data Availability

The following information was supplied regarding data availability:

The isomiRTar portal is available at <https://isomirtar.hse.ru>.

All source codes are available at GitHub: <https://github.com/s-a-nersisyan/isomiRTar>.

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.14205#supplemental-information>.

REFERENCES

- Agarwal V, Bell GW, Nam J-W, Bartel DP. 2015. Predicting effective microRNA target sites in mammalian mRNAs. *ELife* 4:e05005 DOI 10.7554/eLife.05005.
- Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. *Cell* 136:215–233 DOI 10.1016/j.cell.2009.01.002.
- Betel D, Wilson M, Gabow A, Marks DS, Sander C. 2008. The microRNA.org resource: targets and expression. *Nucleic Acids Research* 36:D149–D153 DOI 10.1093/nar/gkm995.
- Bofill-De Ros X, Luke B, Guthridge R, Mudunuri U, Loss M, Gu S. 2021. Tumor IsomiR Encyclopedia (TIE): a pancancer database of miRNA isoforms. *Bioinformatics* 37(18):3023–3025 DOI 10.1093/bioinformatics/btab172.
- Chen Y, Wang X. 2020. miRDB: an online database for prediction of functional microRNA targets. *Nucleic Acids Research* 48:D127–D131 DOI 10.1093/nar/gkz757.
- Clark PM, Loher P, Quann K, Brody J, Londin ER, Rigoutsos I. 2014. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types. *Scientific Reports* 4:5947 DOI 10.1038/srep05947.
- Dongre A, Weinberg RA. 2019. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. *Nature Reviews. Molecular Cell Biology* 20:69–84 DOI 10.1038/s41580-018-0080-4.

- Fang Z, Rajewsky N. 2011. The impact of miRNA target sites in coding sequences and in 3' UTRs. *PLOS ONE* 6:e18067 DOI 10.1371/journal.pone.0018067.
- Forman JJ, Collier HA. 2010. The code within the code: microRNAs target coding regions. *Cell Cycle* 9:1533–1541 DOI 10.4161/cc.9.8.11202.
- Garzon R, Calin GA, Croce CM. 2009. MicroRNAs in cancer. *Annual Review of Medicine* 60:167–179 DOI 10.1146/annurev.med.59.053006.104707.
- Gösgens M, Zhiyanov A, Tikhonov A, Prokhorenkova L. 2021. Good classification measures and how to find them. In: Ranzato M, Beygelzimer A, Dauphin Y, Liang PS, Vaughan JW, eds. *Advances in neural information processing systems*. New York: Curran Associates, Inc, 17136–17147.
- Hagberg A, Schult D, Swart P. 2008. Exploring network structure, dynamics, and function using NetworkX. In: *Proceedings of the 7th python in science conference*. 11–15.
- Harris CR, Millman KJ, van der Walt SJ, Gommers R, Virtanen P, Cournapeau D, Wieser E, Taylor J, Berg S, Smith NJ, Kern R, Picus M, Hoyer S, Van Kerkwijk MH, Brett M, Haldane A, Del Río JF, Wiebe M, Peterson P, Gérard-Marchant P, Sheppard K, Reddy T, Weckesser W, Abbasi H, Gohlke C, Oliphant TE. 2020. Array programming with NumPy. *Nature* 585:357–362 DOI 10.1038/s41586-020-2649-2.
- Hill L, Browne G, Tulchinsky E. 2013. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. *International Journal of Cancer* 132:745–754 DOI 10.1002/ijc.27708.
- Hobert O. 2008. Gene regulation by transcription factors and microRNAs. *Science* 319:1785–1786 DOI 10.1126/science.1151651.
- Hu Z, Jiang K, Frank MB, Chen Y, Jarvis JN. 2016. Complexity and specificity of the neutrophil transcriptomes in juvenile idiopathic arthritis. *Scientific Reports* 6:27453 DOI 10.1038/srep27453.
- Hunter JD. 2007. Matplotlib: a 2D graphics environment. *Computing in Science & Engineering* 9:90–95 DOI 10.1109/MCSE.2007.55.
- Jeffery J, Sinha D, Srihari S, Kalimutho M, Khanna KK. 2016. Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis. *Oncogene* 35:683–690 DOI 10.1038/onc.2015.128.
- Kim CY, Jung WY, Lee HJ, Kim HK, Kim A, Shin BK. 2012. Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma. *Oncology Reports* 27:608–620 DOI 10.3892/or.2011.1545.
- Kozomara A, Birgaoanu M, Griffiths-Jones S. 2019. miRBase: from microRNA sequences to function. *Nucleic Acids Research* 47:D155–D162 DOI 10.1093/nar/gky1141.
- Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, Da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. 2005. Combinatorial microRNA target predictions. *Nature Genetics* 37:495–500 DOI 10.1038/ng1536.
- Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are MicroRNA targets. *Cell* 120:15–20 DOI 10.1016/j.cell.2004.12.035.

- Li Y, Deng X, Zeng X, Peng X. 2016. The role of Mir-148a in cancer. *Journal of Cancer* 7:1233–1241 DOI 10.7150/jca.14616.
- Lin X-L, Yang L, Fu S-W, Lin W-F, Gao Y-J, Chen H-Y, Ge Z-Z. 2017. Overexpression of NOX4 predicts poor prognosis and promotes tumor progression in human colorectal cancer. *Oncotarget* 8:33586–33600 DOI 10.18632/oncotarget.16829.
- Liu W, Wang X. 2019. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. *Genome Biology* 20:18 DOI 10.1186/s13059-019-1629-z.
- Llorens F, Bañez Coronel M, Pantano L, Del Río JA, Ferrer I, Estivill X, Martí E. 2013. A highly expressed miR-101 isomiR is a functional silencing small RNA. *BMC Genomics* 14:104 DOI 10.1186/1471-2164-14-104.
- McKinney W. 2010. Data structures for statistical computing in Python. In: *SciPy 2010*. 56–61 DOI 10.25080/Majora-92bf1922-00a.
- Mercey O, Popa A, Cavard A, Paquet A, Chevalier B, Pons N, Magnone V, Zangari J, Brest P, Zaragosi L-E, Ponzio G, Lebrigand K, Barbry P, Marcet B. 2017. Characterizing isomiR variants within the microRNA-34/449 family. *FEBS Letters* 591:693–705 DOI 10.1002/1873-3468.12595.
- Miranda KC, Huynh T, Tay Y, Ang Y-S, Tam W-L, Thomson AM, Lim B, Rigoutsos I. 2006. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. *Cell* 126:1203–1217 DOI 10.1016/j.cell.2006.07.031.
- Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu A-L, Zhao Y, McDonald H, Zeng T, Hirst M, Eaves CJ, Marra MA. 2008. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. *Genome Research* 18:610–621 DOI 10.1101/gr.7179508.
- Neilsen CT, Goodall GJ, Bracken CP. 2012. IsomiRs—the overlooked repertoire in the dynamic microRNAome. *Trends in Genetics* 28:544–549 DOI 10.1016/j.tig.2012.07.005.
- Nersisyan S, Galatenko A, Chekova M, Tonevitsky A. 2021a. Hypoxia-induced miR-148a downregulation contributes to poor survival in colorectal cancer. *Frontiers in Genetics* 12:662468 DOI 10.3389/fgene.2021.662468.
- Nersisyan S, Galatenko A, Galatenko V, Shkurnikov M, Tonevitsky A. 2021b. miRGTF-net: integrative miRNA-gene-TF network analysis reveals key drivers of breast cancer recurrence. *PLOS ONE* 16:e0249424 DOI 10.1371/journal.pone.0249424.
- Nersisyan S, Shkurnikov M, Poloznikov A, Turchinovich A, Burwinkel B, Anisimov N, Tonevitsky A. 2020a. A post-processing algorithm for miRNA microarray data. *International Journal of Molecular Sciences* 21(4):1228 DOI 10.3390/ijms21041228.
- Nersisyan S, Shkurnikov M, Turchinovich A, Knyazev E, Tonevitsky A. 2020b. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. *PLOS ONE* 15:e0235987 DOI 10.1371/journal.pone.0235987.
- Nilsen TW. 2007. Mechanisms of microRNA-mediated gene regulation in animal cells. *Trends in Genetics* 23:243–249 DOI 10.1016/j.tig.2007.02.011.

- Paquette AG, Shynlova O, Wu X, Kibschull M, Wang K, Price ND, Lye SJ. 2019.** MicroRNA-transcriptome networks in whole blood and monocytes of women undergoing preterm labour. *Journal of Cellular and Molecular Medicine* **23**:6835–6845 DOI [10.1111/jcmm.14567](https://doi.org/10.1111/jcmm.14567).
- Robinson MD, McCarthy DJ, Smyth GK. 2010.** edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**:139–140 DOI [10.1093/bioinformatics/btp616](https://doi.org/10.1093/bioinformatics/btp616).
- Ruff M, Leyme A, Le Cann F, Bonnier D, Le Seyec J, Chesnel F, Fattet L, Rimokh R, Baffet G, Théret N. 2015.** The disintegrin and metalloprotease ADAM12 is associated with TGF- β -Induced epithelial to mesenchymal transition. *PLOS ONE* **10**:e0139179 DOI [10.1371/journal.pone.0139179](https://doi.org/10.1371/journal.pone.0139179).
- Shao N-Y, Hu HY, Yan Z, Xu Y, Hu H, Menzel C, Li N, Chen W, Khaitovich P. 2010.** Comprehensive survey of human brain microRNA by deep sequencing. *BMC Genomics* **11**:409 DOI [10.1186/1471-2164-11-409](https://doi.org/10.1186/1471-2164-11-409).
- Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. 2022.** DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucleic Acids Research* **50**(W1):W216–W221 DOI [10.1093/nar/gkac194](https://doi.org/10.1093/nar/gkac194).
- Sie Z-L, Li R-Y, Sampurna BP, Hsu P-J, Liu S-C, Wang H-D, Huang C-L, Yuh C-H. 2020.** WNK1 kinase stimulates angiogenesis to promote tumor growth and metastasis. *Cancer* **12**(3):575 DOI [10.3390/cancers12030575](https://doi.org/10.3390/cancers12030575).
- Tan GC, Chan E, Molnar A, Sarkar R, Alexieva D, Isa IM, Robinson S, Zhang S, Ellis P, Langford CF, Guillot PV, Chandrashekrana A, Fisk NM, Castellano L, Meister G, Winston RM, Cui W, Baulcombe D, Dibb NJ. 2014.** 5' isomiR variation is of functional and evolutionary importance. *Nucleic Acids Research* **42**:9424–9435 DOI [10.1093/nar/gku656](https://doi.org/10.1093/nar/gku656).
- Telonis AG, Loher P, Jing Y, Londin E, Rigoutsos I. 2015.** Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity. *Nucleic Acids Research* **43**:9158–9175 DOI [10.1093/nar/gkv922](https://doi.org/10.1093/nar/gkv922).
- Telonis AG, Magee R, Loher P, Chervoneva I, Londin E, Rigoutsos I. 2017.** Knowledge about the presence or absence of miRNA isoforms (isomiRs) can successfully discriminate amongst 32 TCGA cancer types. *Nucleic Acids Research* **45**:2973–2985 DOI [10.1093/nar/gkx082](https://doi.org/10.1093/nar/gkx082).
- van der Kwast RVCT, Woudenberg T, Quax PHA, Nossent AY. 2020.** MicroRNA-411 and its 5'-IsomiR have distinct targets and functions and are differentially regulated in the vasculature under ischemia. *Molecular Therapy: The Journal of the American Society of Gene Therapy* **28**:157–170 DOI [10.1016/j.ymthe.2019.10.002](https://doi.org/10.1016/j.ymthe.2019.10.002).
- Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, Burovski E, Peterson P, Weckesser W, Bright J, van der Walt SJ, Brett M, Wilson J, Millman KJ, Mayorov N, Nelson ARJ, Jones E, Kern R, Larson E, Carey CJ, Polat I, Feng Y, Moore EW, VanderPlas J, Laxalde D, Perktold J, Cimrman R, Henriksen I, Quintero EA, Harris CR, Archibald AM, Ribeiro AH, Pedregosa F, Van Mulbregt**

- P, SciPy 1.0 Contributors. 2020.** SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nature Methods* **17**:261–272 DOI [10.1038/s41592-019-0686-2](https://doi.org/10.1038/s41592-019-0686-2).
- Visone R, Croce CM. 2009.** MiRNAs and cancer. *American Journal of Pathology* **174**:1131–1138 DOI [10.2353/ajpath.2009.080794](https://doi.org/10.2353/ajpath.2009.080794).
- Wang C-Z, Deng F, Li H, Wang D-D, Zhang W, Ding L, Tang J-H. 2018.** MiR-101: a potential therapeutic target of cancers. *American Journal of Translational Research* **10**:3310–3321.
- Waskom M. 2021.** seaborn: statistical data visualization. *Journal of Open Source Software* **6**:3021 DOI [10.21105/joss.03021](https://doi.org/10.21105/joss.03021).
- Yu F, Pillman KA, Neilsen CT, Toubia J, Lawrence DM, Tsykin A, Gantier MP, Callen DF, Goodall GJ, Bracken CP. 2017.** Naturally existing isoforms of miR-222 have distinct functions. *Nucleic Acids Research* **45**:11371–11385 DOI [10.1093/nar/gkx788](https://doi.org/10.1093/nar/gkx788).
- Zhang Y, Zang Q, Xu B, Zheng W, Ban R, Zhang H, Yang Y, Hao Q, Iqbal F, Li A, Shi Q. 2016.** IsomiR bank: a research resource for tracking IsomiRs. *Bioinformatics* **32**:2069–2071 DOI [10.1093/bioinformatics/btw070](https://doi.org/10.1093/bioinformatics/btw070).
- Zhiyanov A, Nersisyan S, Tonevitsky A. 2021.** Hairpin sequence and structure is associated with features of isomiR biogenesis. *RNA Biology* **18**:430–438 DOI [10.1080/15476286.2021.1952759](https://doi.org/10.1080/15476286.2021.1952759).